New pill for bile duct cancer after prior treatment
Part of Cancer clinical trials.
This trial tests a new pill (3D185) that targets a specific gene change (FGF/FGFR) found in some bile duct cancers. It's for patients whose cancer has grown after standard treatments. The drug works by blocking signals that help cancer cells grow, potentially slowing the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bile duct cancer that has spread or cannot be removed by surgery.
- Your cancer has grown despite at least one previous cancer treatment.
- Your tumor has a change in the FGF or FGFR gene (this will be tested).
- You have tumors that can be measured on a scan.
- You are able to take care of yourself (up and about, not bedridden).
- You have not taken a drug that blocks FGFR before, and you have no significant eye or calcium buildup problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called pemigatinib for people with bile duct cancer that has spread and has a specific gene change (FGFR2 fusion or rearrangement). It may slow or stop tumor growth. The study is for those whose cancer has progressed after at least one prior treatment.
This trial is testing treatments that are customized to the specific genetic changes in your bile duct or gallbladder cancer. The goal is to find a drug that targets your tumor's unique mutation, which may help control the cancer better than a one-size-fits-all approach.
This trial tests HMPL-453 to treat advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 change. It may help shrink tumors or control the disease in people whose cancer has not responded well to prior treatment.
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
This study tests a new treatment combination for advanced bile duct or gallbladder cancer that has not been treated before. It aims to slow cancer growth and may be a good option if you have not had prior therapy for your cancer.
Hear when a new Cholangiocarcinoma,Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.